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B lymphocytes may be activated by a variety of agents, including antigens and 
mitogens. The minimum stage of  activation so far demonstrated has been passage 
from the resting Go stage into an activated GI phase. This is operationally defined 
as blastogenesis, and is marked by increased RNA synthesis and expression of 
surface  markers  characteristic  of proliferating cells  in  the  absence  of DNA 
synthesis (1-3).  In the presence of appropriate soluble factors, these cells will 
proliferate, then terminally differentiate into antibody-secreting plasma cells. 
Epstein-Barr  virus  (EBV) 1 infects resting  B  cells  (4-9)  and  drives  them  to 
differentiate into  Ig-secreting lymphoblasts (10,  11)  that  express  cell  surface 
markers characteristic of  activated B cells (12, 13). These lymphoblasts proliferate 
indefinitely in culture (14,  15), a process that has been termed growth transfor- 
mation or immortalization. 
We  have  proposed  (12)  that  growth  transformation by  EBV  involves  two 
processes. The first parallels the normal differentiation pathway for resting B 
cells whereby they become activated and proliferate. The second involves the 
fixing of the lymphoblasts at this stage, leading to indefinite proliferation. Thus, 
the mechanism of B cell activation is intricately involved with the process of EBV 
infection. In addition, EBV has several advantages over other systems, such as 
anti-IgM or mitogens, for studying the activation of resting B cells.  There are 
clear-cut markers for the presence of the activating signal (EBV DNA, and virus- 
encoded antigens), and activation of a large fraction (up to 40%) (5,  16) of the 
B cells may be obtained with a fairly synchronous order of events. These include 
the  induction of a  viral  nuclear antigen (EBNA)  by  24  h,  and blastogenesis, 
proliferation, and expression of p63  (an EBV-encoded membrane protein) (17 
and Mann et al. submitted), between 48 and 72  h.  Furthermore, no accessory 
cells are required, and EBV-infected cells are immortalized at a particular stage 
of differentiation, allowing access to bulk quantities of defined cells for biochem- 
ical  analysis.  We  have  previously used  the  EBV  system to  describe  a  B  cell 
activation antigen, BLAST-1 (12). This marker was not found on resting B cells, 
but  was  detected  on  their  surface  when  they  underwent  blastogenesis after 
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activation  by mitogens,  antigen,  or  EBV.  Using the  EBV cell  surface (EBVCS) 
monoclonal  antibodies  (mAb)  (18),  we  have  been  able  to  describe  a  second 
activation antigen,  BLAST-2  (EBVCS),  which  is also B  cell-specific.  However, 
this marker was different from BLAST-l, as it was detected  within  24 h  of the 
activation signal, well before the time of blastogenesis. 
Our previous experiments were conducted  on bulk cultures,  and the level of 
expression and number of BLAST-2 ÷ ceils was low. Therefore, it was not possible 
to  tell  whether  the  BLAST-2  (EBVCS)  ÷ cells present  soon after  the  activation 
signal  were  the  same cells that  would  subsequently  undergo  blastogenesis  and 
proliferation. 
In this report, we use the  EBV system to study the  BLAST-2  (EBVCS)  + and 
BLAST-2- populations early after infection.  We show that the BLAST-2 + cells 
are small  lymphocytes, clearly distinct  from proliferating  lymphoblasts.  Never- 
theless,  when  these  cells are  placed  back  in  culture,  they  proceed  to  undergo 
transformation  into  B  lymphoblasts.  Thus,  we  conclude  that  B  cell  activation 
proceeds through  two distinct  steps;  the first occurs within  24 h, and is charac- 
terized by expression of the BLAST-2 (EBVCS) antigen and induction  of RNA 
synthesis; the second occurs later, and is associated with blastogenesis, prolifera- 
tion,  and  expression  of  BLAST-1.  Furthermore,  BLAST-2  (EBVCS)  is  the 
earliest B cell-specific cell surface marker so far identified for activated B cells. 
Materials and  Methods 
Cells.  Freshly transformed B lymphocytes were prepared as follows: 2-3 ml of packed 
buffy-coat cells were obtained by centrifugation of plasmapheresis by-product material 
(Red Cross,  Boston  MA)  over Ficoll-hypaque.  The cells were washed once in  medium 
(RPMI 1640 plus 5% fetal calf serum), and B lymphocytes were isolated by passage over 
a column of rabbit anti-human Fab  coupled to Sephadex G-200 (19, 20). ~ 109 cells were 
passed over each column of 12 ml packed bed volume. The column was washed thoroughly 
with medium plus  1 mM EDTA (column buffer), and the adhered B lymphocytes were 
then removed by stirring in the presence of column buffer supplemented with 1% human 
gamma globulin, Cohn Fraction II (Sigma Chemical Co., St. Louis, MO). Typically, 10- 
15 % of the lymphocytes were recovered in the Ig  + population, yielding 2-3 x  10  a purified 
B cells. This population will be referred to as peripheral blood lymphocyte (PBL)-B cells, 
and was usually >90% B ceils by the criteria of surface Ig and B1 (21) antigen expression, 
and <1% T  cells using the T3 surface marker. These cells were infected at a density of 
4 ×  106 cells/ml with EBV from the culture supernatant of the B95-8 lymphoblastoid cell 
line (TDs0 ~5 ×  105). TDs0 was estimated by limiting-dilution analysis on constant numbers 
of purified B cells.  Our experiments show that such  EBV-infected cells have a  cloning 
efficiency of 1-2% on a  feeder layer of irradiated  human foreskin fibroblasts (350  Q). 
Thus our estimated TDs0 is -50-100-fold lower than the actual number of infectious 
particles (i.e.  ~107 viruses/ml).  Infection was either with undiluted  supernatant, or with 
supernatant  diluted  1:2  or  1:4  with  medium  containing  20%  fetal  calf serum.  When 
undiluted virus was used, half of the volume was replaced with medium after 2 h at 37°C. 
The three dilutions of virus generally gave 12-18%, 7-12%, and 3-7 % BLAST-2  ÷ cells, 
respectively, at 36 h postinfection. Visual assessment was used to measure growth trans- 
formation; our criteria have been described in detail elsewhere (20).  Briefly, a culture in 
a  microtiter well was regarded as growth transformed if it contained large numbers of 
proliferating lymphoblasts, both as single cells and  clumps. With  the dilutions of virus 
supernatant  used  in  these  experiments (see above), growth  transformation was always 
achieved within  10 d postinfection. 
Cytofluorographic Analysis.  Cells from infected cultures were washed twice with RPMI- 
1640  supplemented with  1%  fetal calf serum (medium), and cells were resuspended  in 
anti-BLAST-2 (EBVCS) hybridoma ascites fluid. The hybridoma used was EBVCS 2 (18), THORLEY-LAWSON  AND  MANN  47 
kindly provided by Dr. B. Sugden, and shown previously in this laboratory to define the 
BLAST-2  (EBVCS)  antigen  (13)  and  the  anti-BLAST-1  previously  described  by  this 
laboratory (12). Fluorescence analysis revealed that these ascites had a titer of I:104-10  ~ 
and  1:10~-103,  respectively, and were routinely used at  1:100 or  1:50 dilution,  respec- 
tively, thus assuring saturation. Unreactive mAb of the same isotypes were used as negative 
controls. For analysis, 106 cells were resuspended in  100 ~1 of antibody, and for sorting 
experiments, 2-3 ×  107 cells were labelled in separate tubes, each with 200 #l of antibody. 
The cells were then incubated on ice for 20 min, washed twice, and resuspended in 0.1 
or  0.2  ml  of fluorescein  isothiocyanate  (FITC)-labelled goat anti-mouse  Ig (Cappell) 
diluted  1:20. After a further 20 rain incubation at 4 °C, the cells were washed twice, and 
resuspended either in  1 ml for analytical experiments (106 cells/ml), or 5 ml for sorting 
experiments (5 ×  106 cells/ml). 
For the analysis of cell cycle stage, the FITC-labelled cells were costained with propidium 
iodide. The labelled cells (106) were resuspended in 0.5 ml of phosphate-buffered saline 
(PBS), and an equal volume of 100% ethanol was added slowly while vortexing vigorously. 
Alcohol fixation was found previously (our unpublished observations) not to affect the 
fluorescence due to the labelled BLAST-2 (EBVCS) antigen.  The cells were incubated 
for at least 1 h at 4°C, then washed once with PBS and resuspended in 250 ~l of 500 U/ 
ml ribonuclease A (Sigma Chemical Corp.) in  1.12% sodium citrate buffer, pH 8.4. This 
mixture  was  incubated  for  30  min  at  37°C,  and  then  an  equal  volume  (250  ul)  of 
propidium iodide (50 gg/ml) in I. 12% sodium citrate buffer was added and the mixture, 
incubated  for an  additional  30  min at room temperature.  Specific RNA  staining was 
performed exactly as described (22) by using the Hoechst 33342 and Pyronin Y dyes. 
Analysis was performed on a  fluorescence-activated cell sorter (FACS) analyzer, and 
sorting was done on a FACS III or FACS IV cell sorter. For cell size and cell cycle studies, 
the  most  fluorescent  population  was  identified,  and  gates  set  accordingly.  The  size 
distribution or staining profile of this population was then assessed. For sorting experi- 
ments, only small lymphocytes were collected, to avoid contamination by lymphoblasts or 
monocytes.  Usually,  collecting the  20%  most and  least fluorescent cells  gave the  best 
yields and  purity  of the  BLAST-2  (EBVCS)  ÷ and  BLAST-2-  populations.  Generally, 
positive selection yielded a population >60% BLAST-2 (EBVCS)  ÷, and negative selection 
gave a population < 1% BLAST-2 (EBVCS)  ÷. An example of such dual analysis is presented 
in Fig.  3.  For sorting on the basis of RNA content,  the high and low populations were 
separated (see Fig.  5), and the gates were set to collect whole populations. Cloning was 
performed  using  a  Coulter  autocloner,  previously  calibrated  with  fluorescent  beads. 
Microtiter plates containing  1,  10, and  100 cells/well were established on a feeder layer 
of irradiated human foreskin fibroblasts (350 Q). 
Hybridization.  Cells were washed once with PBS and resuspended to 108 cells/ml.  10  6 
cells were routinely spotted onto nitrocellulose (Bio-Rad Laboratories, Richmond, CA) as 
two 5-~1 aliquots, with drying in between. Thereafter, the procedure used was the colony 
hybridization method of Grunstein and Hogness (23), as modified by Brandsma and Miller 
(24) for lymphoid cells. The Barn H 1 V fragment (kind gift of T. Dambaugh) was used as 
a probe. 
lnhibitors.  The  concentrations  of metabolic  inhibitors  chosen  were  the  maximum 
necessary to obtain inhibition without affecting viability of an EBV-transformed lympho- 
blastoid cell line after 2 d of culture. The following inhibitors were used: cycloheximide 
(5  #g/ml), actinomycin D  (1  #g/ml),  arabinoside C  (1  ug/ml), and acyclovir (100  uM). 
lnhibitors were added to culture, at the dosage described, 1 h before infection, and were 
maintained in the culture throughout the course of the experiment. 
EBNA Stain.  Staining for EBNA was carried out by the standard technique described 
previously by Reedman and Klein (25), using EBNA  ÷ and EBNA- sera characterized and 
kindly supplied by Dr. G. Klein (Karolinska Institute, Stockholm, Sweden). 
Results 
The BLAST-2  (EBVCS) Antigen  is Expressed  Before  Transformation.  We  have 
shown  previously  (13)  that  the  BLAST-2  (EBVCS)  antigen  is expressed  on  B 48  EBV  AND  B  CELL  ACTIVATION 
cells  within  24  hours  after  EBV  infection.  This  is  well  before  the  time  of 
blastogenesis and proliferation,  which occur 2-3 d  postinfection (5,  26,  16). An 
example of such an experiment is shown in Fig.  1. 
EBV-infected  PBL-B were tested at various times postinfection for the expres- 
sion  of the  BLAST-2  (EBVCS)  antigen.  The  cells  were  stained  with  the  anti- 
BLAST-2  (EBVCS)  mAb, and analyzed  by cytofluorography.  Within  1  d  post- 
infection, -10%  of the cells expressed the BLAST-2 (EBVCS) antigen.  A  typical 
example of the fluorescence  profile obtained with cells at this time is shown in 
Fig.  2.  The  BLAST-2 ÷ cells  are  clearly  resolved as a  distinct  population.  This 
population was absent from a  negative control of the same cells stained with an 
unreactive  mAb of the same  Ig class as anti-BLAST-2  (EBVCS).  Interestingly, 
LCL 
14  /  O~Stl2  05~ 
IC  81O$t-I  63 
~  4 
2 
2  3  4  5 
Days Postinfection 
FIGURE  l.  Expression of the BLAST-1 and BLAST-2 antigens on EBV-infected PBL-B cells. 
Freshly isolated PBL-B cells (4 x  106 cells/ml) were infected with B95-8 virus (tissue culture 
supernatant  diluted  1:1  with medium) and placed in culture. Cells were recovered each day 
and stained with either anti-BLAST-1  or anti-BLAST-2 (EBVCS) mAb followed by  FITC- 
conjugated  rabbit  anti-mouse  Ig, and  cytofluorographic analysis was performed.  The  per- 
centage of positive cells was assessed by subtraction of background fluorescence obtained with 
a negative control mAb. The BLAST-2 (EBVCS) data represent means of three independent 
experiments. The BLAST-I data is from a single experiment. LCL, established lymphoblastoid 
cell line. 
FIGURE 2.  Fluorescence profile of PBL-B cells stained with anti-BLAST-2 (EBVCS) at 36 h 
postinfection. Infected cells were prepared and labelled as described in the legend to Fig.  1. 
Each histogram  represents the analysis of 10,000  cells.  An arbitrary cut off line (A-A') has 
been drawn  to  highlight tbe population  of positive cells.  (Top) stained  with anti-BLAST-2 
(EBVCS). (Bottom)  stained with negative control mAb. THORLEY-LAWSON AND MANN  49 
the three dimensional plot indicates that, at this time, the BLAST-2 ÷ cells are of 
the same size as the bulk of the cells in the culture, which are small resting PBL- 
B cells (see below). 
The time of appearance of B lymphoblasts was demonstrated by staining with 
the anti-BLAST-1  mAb (Fig.  1).  As may be seen in  Fig.  1,  BLAST-l-reactive 
cells were not detected until 2 d after the appearance of BLAST-2 (EBVCS). 
Expression of the BLAST-2 (EBVCS)  Antigen Predicts Transformation.  The ex- 
periments described previously and exemplified above lead to  the hypothesis 
that expression of the BLAST-2 (EBVCS) antigen indicates that a cell is activated 
and  will  undergo blastogenesis  and  proliferation.  To  test  this  prediction,  we 
separated  the  BLAST-2  (EBVCS)  +  from  BLAST-2-  populations,  and  placed 
them in culture. Infected B cells were labelled by indirect immunofluorescence 
using the BLAST-2 (EBVCS) mAb or an unreactive antibody of the same class. 
The 20%  most and least fluorescent cells were isolated using a  FACS III cell 
sorter  under  sterile  conditions,  and  were  placed  back  in  culture  alongside 
unfractionated cells.  Upon reanalysis, there were  15%  BLAST-2 + cells in  the 
unfractionated population; 60% in the positively selected population, and <1% 
in the negatively selected population (Fig. 3). The cultures were assessed visually 
for growth transformation immediately after plating, and daily thereafter. Fig. 
3  shows photographs of the three cultures taken immediately after separation 
(day 2), and 8 d  later (day 10).  The cultures were essentially indistinguishable 
when first plated; however, extensive overgrowth of the wells by proliferating 
lymphoblasts was seen only in the culture from the BLAST-2 + cells, Proliferation 
in  the unseparated population  was also seen, but at a  much lower level, with 
complete outgrowth seen in all of the cultures only by the end of the experiment 
(day 10). In contrast, no outgrowth, and only an occasional lymphoblast was seen 
in  any  of the  cultures  from  the  BLAST-2-  cell  population  by  the  time  the 
experiment was terminated. 
Staining with  the monocyte-specific antibody  MO-2  (27)  suggests  (data not 
shown) that monocytes are the only major contaminating cell population (as high 
as  10%) of our purified B cells. It was, therefore, possible that our 20%  least 
fluorescent population  was enriched for monocytes, and thus would not have 
proliferated  and  overgrown  the  culture  well.  Three  observations  make  this 
explanation unlikely: (a) a size gate characteristic of small lymphocytes was used 
for the sorting, and since monocytes are usually larger, they would have been 
excluded; (b) most monocytes would have adhered to the plastic dishes during 
the  culture  period;  and  (c) reanalysis revealed that  the  BLAST-2  (EBVCS)- 
population of cells readily reacted with the B cell-specific antibody B 1 (21), but 
no detectable reaction (<1%) was seen with the monocyte-specific antibody MO- 
2 (27), nor with the pan-T cell specific mAb T3. 
A  further, quantitative  indication of the relationship between proliferation 
and BLAST-2 (EBVCS) expression was obtained by plating various numbers of 
BLAST-2  (EBVCS)  +  and  BLAST-2-  cells  in  microwells,  and  assessing  the 
number of wells outgrown by day  10.  As seen in  Table  I, no outgrowth of 
the negatively selected cells was seen at the highest cell number used, 5  x  105 50  EBV  AND  B  CELL  ACTIVATION THORLEY-LAWSON  AND  MANN  51 
TABLE  I 
Outgrowth of Unseparated  and BLAST-2 (EBVCS) ÷- and BLAST-2- 
Populations 
Plating density 
Wells outgrown 
Unseparated  BLAST-2  ÷  BLAST-2- 
Cells/ml 
5x  10 s  6  0  6 
2x  105  6  0  6 
1  x  105  2  0  6 
5x  104  0  0  6 
2 x  104  0  0  6 
1  X  10 4  0  0  6 
The cell populations used were the same as described in the legend to Fig. 
3.  0.2 ml of cell suspension at the given cell density were plated out in 
flat-bottomed microtiter plates and assessed visually for growth transfor- 
mation at 10 d. Six wells were tested per group. 
cells/ml. By comparison, outgrowth of unfractionated cells was seen at as low as 
105 cells/ml, with one third of the wells being BLAST-2  +, whereas outgrowth of 
the positively selected population was seen in all wells at the lowest cell number 
tested (104 cells/ml). 
We wished to obtain an estimate of the fraction of BLAST-2 (EBVCS)  + cells 
that would undergo blastogenesis and outgrowth. To do this, the cloning effi- 
ciency of these cells was compared to that of a recently established cell line. Cells 
at 36 h postinfection were sterilely sorted, as described above, and cloned, using 
a  Coulter autocloner, onto microtiter plates at a  cell number of 100,  10,  or  1 
cell/well on a  human fibroblast feeder layer. As a  control, the same cells were 
also  cloned  at  14  d  postinfection,  by  which  time  all  of the  cells  are  growth 
transformed. The sort parameters are given in the legend to Table II. In Table 
II, the BLAST-2 (EBVCS)  + cells had a preblastogenesis cloning efficiency (1.7%, 
or 1.9% when corrected for fraction of BLAST-2 ÷ cells) similar to the established 
line (1.6%).  Moreover, when the cloning efficiency for the unfractionated pop- 
ulation at 36 h (0.27%) was corrected for the fraction of cells expressing BLAST- 
2 (EBVCS), a cloning efficiency (1.8%) similar to that of the established line was 
again  obtained.  No  outgrowth  was  seen  in  any  wells  containing  BLAST-2 
(EBVCS)-  cells. 
Thus,  we may conclude  that the BLAST-2  (EBVCS) + cells at 36 h  postinfection 
clone  with  a  similar  efficiency  to  that  of established  EBV-growth-transformed 
cells. This  is consistent  with all of the  BLAST-2  (EBVCS) + cells being  activated, 
and  undergoing  blastogenesis  and  subsequent  proliferation. 
FIGURE 3.  Capacity  of the  BLAST-2  (EBVCS)  ÷ and  BLAST-2-.populations  to  undergo 
subsequent transformation.  108 PBL-B cells were infected at 4  x  10° cells/ml with undiluted 
supernatant from the B95-8 lymphoblastoid cell line. 36 h postinfection, the cells were stained 
with anti-BLAST-2 (EBVCS) and analyzed with a  FACS IV cell sorter. The 20%  most and 
least fluorescent populations (top) were then sterilely separated.  Reanalyses of the two popu- 
lations are presented in the middle and lower panels. The 20% level was selected by comparison 
to the staining obtained with a  negative control antibody, so as to give the highest yield of 
BLASTo2 (EBVCS)  ÷ cells with the lowest level of contamination  with BLAST-2 (EBVCS)- 
cells. In the reanalyses, < 1% of the negatively selected, and 60% of the positively selected cells 
expressed BLAST-2 (EBVCS). The cells were then placed back in culture and assessed daily 
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TABLE II 
Cloning Efficiency of BLAST-2 (EBVCS)  +, BLAST-2-, and Unseparated Populations Before 
Transformation Compared to the Established Cell Line 14 d Postinfection 
Cells/Well 
Cloning efficiency after 36 h in culture  Cloning  efficiency 
of established line 
Unseparated  BLAST-2  ÷  BLAST-2-  14 d in culture 
1  0  0  0  0 
10  3/96  16/96  0  14/86 
100  26/96  43/43  0  96/96 
Cloning efficiency:  0.27  1.7  <0.01  1.6* 
Cloning efficiency (per cent 
per BLAST-2  ÷ cell):  1.8  1.9  1.6 
In this experiment, the unseparated culture contained 15% BLAST-2 (EBVCS)  ÷ cells. The positive 
and negative populations were obtained by selecting the 10% most and least fluorescent cells. Upon 
reanalysis, the positive population contained 89% and the negative populations contained <1% 
BLAST-2 (EBVCS)  ÷ cells. Cloning efficiency was estimated after 6 wk in culture. 
Size  and  DNA  Content  of  the  BLAST-2  (EBVCS)  +  Cells.  If  the  BLAST-2 
(EBVCS)  + cells that are detected on day  1 and day 2  postinfection have yet to 
undergo blastogenesis, they should have levels of DNA synthesis and size char- 
acteristic  of resting  PBL-B, and  not  of proliferating  lymphoblasts.  Our  initial 
analysis, of the kind shown in Fig.  2, suggests that this was indeed the case. To 
test this directly, the BLAST-2 (EBVCS)  + cells were analyzed 36 h postinfection 
for size, and number of dividing cells. Using a  FACS analyzer, it was possible to 
gate only on the BLAST-2 (EBVCS)  ÷ population, and generate a size distribution 
curve. As may be seen in Fig. 4, this cell population had both a peak and mean 
cell volume indistinguishable  from that obtained with purified uninfected PBL- 
B  cells,  but clearly distinct  from that  obtained with  EBV-growth-transformed 
lymphoblasts.  Similarly,  when  this  same  population  was  analyzed  for  DNA 
content using the propidium iodide stain (Fig. 4), essentially all of the cells were 
diploid, and, therefore, in the G0-G1 phase of the cell cycle, as was seen with the 
uninfected  PBL-B  cells.  By  comparison,  more  than  half  of the  cells  in  the 
lymphoblastoid cell line were in the S-G2-M phases of the cell cycle, characteristic 
of actively growing cells. 
We conclude, therefore, that the BLAST-2 (EBVCS) antigen is expressed on 
a population of small resting B lymphocytes before blastogenesis. 
RNA Content of the BLAST-2 (EBVCS)  + Cells.  Another parameter for assessing 
the activation state of EBV-infected cells is the level of RNA synthesis. To assess 
relative  RNA  content,  the  small  EBV-infected B  cells were  stained  for  RNA 
content at  36 h  postinfection using the Hoechst 33342 and Pyronin Y  double- 
staining method (22). As may be seen in Fig. 5 C the infected B cells contain two 
distinct populations,  one with a  level of RNA  similar to that of resting B  cells 
(Fig.  5A); and one, constituting 42% of the cells,  with a  higher level of RNA, 
similar  to  that  of proliferating  lymphoblasts  (Fig.  5B).  When  the  BLAST-2 
(EBVCS)  + cells were analyzed for RNA content, it was found (Fig. 5D) that they 
all expressed high levels of RNA, consistent with all being activated. 
EBV Genetic Information  in the BLAST-2 (EBVCS)  ÷ Population.  In the experi- 
ment described above, there was a  marked discrepancy between the percentage THORLEY-LAWSON  AND  MANN  53 
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FIGURE 4.  Size  and  cell  cycle  stage  of the  BLAST-2  (EBVCS)  ÷ cells 36  h  postinfection. 
Infected PBL-B cells were prepared and labelled as described for Fig. 1. In addition, uninfected 
PBL-B cells and an EBV-transformed lymphoblastoid cell line were studied. (Left)  Using a 
FACS analyzer, the population of cells fluorescently labelled with anti-BLAST-2 (EBVCS) 
were gated, then analyzed for their size distribution in comparison to uninfected PBL-B cells 
or a  transformed lymphoblastoid cell  line. (Right)  As above, except the cells were double- 
labelled with the DNA stain propidium iodide, and the BLAST-2 (EBVCS)  ÷ cells were assessed 
for  their cell  cycle  stage  on  the  basis of their degree  of labelling with  propidium  iodide 
compared to resting, uninfected PBL-B cells and an actively proliferating lymphoblastoid cell 
line. 
of activated cells as assessed by BLAST-2 (EBVCS) expression (12%) compared 
to elevated RNA content (42%).  However, the cloning experiments described 
above indicated that only the BLAST-2 (EBVCS)  + cells became immortalized. 
An alternative approach  to assessing whether EBV  bad  infected and thereby 
activated the B cells was to stain  them for EBNA.  Table III summarizes data 
from two experiments. Essentially all of the BLAST-2 (EBVCS)  + cells were also 
EBNA  +, consistent with the results of the outgrowth experiment. However, most 
of the RNA-active cells were also EBNA  +, indicating that there was a substantial 
fraction of cells that are EBNA  + and RNA active that did not express detectable 
levels of BLAST-2  (EBVCS).  Furthermore,  these cells do  not  grow  out  into 
established cell lines, as the cloning experiment indicates no detectable outgrowth 
with BLAST-2 (EBVCS)- cells.  We may conclude, therefore, that in an infected 
culture, at 36  h  there are three types of small nondividing cells:  (a) those that 
lack detectable BLAST-2 (EBVCS), do not express EBNA, and are not synthe- 54  EBV  AND  B  CELL  ACTIVATION 
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FIGURE 5.  RNA content of BLAST-2 (EBVCS)+ cells.  36 h postinfection, PBL-B cells were 
infected with EBV and cultured for 36 h. The cells were then stained for BLAST-2 (EBVCS) 
expression and for RNA using the method described by Shapiro (22).  (A) Resting uninfected 
PBL-B cells. (B) Recently established lymphoblastoid cell line. (C) Whole infected PBL-B cells. 
(D) BLAST-2 (EBVCS)  + infected PBL-B cells.  There were 12%  BLAST-2 (EBVCS)  ÷ cells in 
the whole infected PBL-B cell population in this experiment. 
TABLE  III 
Expression  of EBNA and Elevated Levels of RNA in BLAST-2 (EBVCS) + 
and BLAST-2- Populations 
Out-  Total cells  EBNA  + cells  RNA elevated  growth* 
BLAST-2  +  12  90 
RNA Elevated  42  87 
EBNA  +  45 
% 
89.9  + 
BLAST-2-  88  38$ 
RNA Resting  58  10 
EBNA-  55 
33.7 
* Taken from experiments shown in Tables I and II. 
Estimated from the percent EBNA  + cells in the total population, the percent 
of BLAST-2 (EBVCS)  ÷ cells and the percent EBNA  ÷ cells in that population. 
sizing  RNA  (45-55%;  Table  III);  (b)  those  that  lack  detectable  BLAST-2 
(EBVCS), but do express EBNA, and are actively synthesizing RNA (30-40%; 
Table  III);  and  (c)  those  that  do  express  detectable  BLAST-2  (EBVCS)  and 
EBNA,  and  are  synthesizing  RNA  (10-15%;  Table  III).  This  last  population 
completes the activation process and becomes a line of established proliferating 
lymphoblasts. 
EBV  Genome  in  the  BLAST-2  (EBVCS)  + and  BLAST-2-  Populations.  If  the 
BLAST-2  (EBVCS)  +  PBL-B  cells  that  occur  after  infection  are  destined  to 
undergo blastogenesis and proliferate into continuously growing lymphoblastoid 
cell lines,  they should contain  EBV genomes, in addition  to expressing EBNA. 
To  test  this  prediction,  the  BLAST-2  (EBVCS)  + and  BLAST-2-  populations 
were separated  and  collected as described above, except that  a  FACS  IV  was 
used.  ~ 106 ceils of each  population  and  of the  unfractionated  cell population 
were  then  blotted  onto  nitrocellulose  paper.  RAJI  cells,  an  EBV  +  Burkitt's 
lymphoma line with ~60 intact viral genomes (28), and RAMOS cells, an EBV- 
Burkitt's  lymphoma  line  (29)  were blotted  as controls.  The  presence  of EBV 
DNA was then detected by probing the blots witb the Bam H 1 V  fragment  of 
the  EBV  genome.  The  autoradiogram  obtained  from  the  hybridized  filter  is THORLEY-LAWSON  AND  MANN  55 
shown  in  Fig.  6.  This result demonstrates qualitatively that  EBV  genetic  infor- 
mation was readily found in the unfractionated and BLAST-2 (EBVCS)  + popu- 
lations.  Furthermore,  the hybridization signal was enriched after isolation of the 
BLAST-2 (EBVCS)  + cells with an intensity on the autoradiogram suggestive of 
multiple  EBV genome copies.  More surprisingly,  we were unable  to detect any 
EBV  DNA  in  the  BLAST-2  (EBVCS)-  population  (see discussion).  No hybridi- 
zation was seen to the negative control RAMOS cell line, and a  strong signal was 
obtained  with  the  positive  control  RAJI  cell  line.  These  results  lead  to  the 
conclusion  that  the  BLAST-2  (EBVCS)  +  population  already  contains  multiple 
copies of the EBV genome. 
Expression of  BLAST-2 (EBVCS) in the Presence of  Metabolic Inhibition.  As shown 
above, the expression of BLAST-2 (EBVCS) upon EBV infection occurs before 
detectable cellular DNA synthesis or cell division, but concomittant with raised 
levels of RNA.  To define whether the appearance of BLAST-2 (EBVCS) was a 
consequence of de novo synthesis, or exposure of cryptic antigen,  we attempted 
to block the expression with various metabolic inhibitors.  As shown in Table IV, 
the  presence  of the  DNA  synthesis  inhibitor  arabinoside  c  did  not  affect the 
expression of BLAST-2 (EBVCS).  However, BLAST-2 (EBVCS) expression was 
prevented by a  protein  synthesis  inhibitor  (cycloheximide),  and an  inhibitor  of 
RNA synthesis (actinomycin D).  These experiments suggest, therefore, that the 
gene encoding BLAST-2 (EBVCS) may be activated upon EBV infection, rather 
than EBV infection causing the surface expression of BLAST-2 (EBVCS) mole- 
cules already present. 
FIGURE 6.  Detection of EBV genetic information  in the BLAST-2  ÷ and BLAST-2- popula- 
tions. BLAST-2 (EBVCS)- and BLAST-2  + cell populations were obtained by sorting infected 
PBL-B cells at 36 h postinfection, as described  in Fig. 4.  l0  s cells of each population  were 
then blotted onto nitrocellulose, along with the unselected population. The cell lines RAMOS 
and RAJI were used as negative and positive controls, respectively. In addition, a mixture of 
RAMOS and RAJI, which should yield an average genome number around 1, was also applied. 
All cell types are present in duplicate, with the exception of the sorted (BLAST-2 (EBVCS)~ 
and BLAST-2  ÷) populations,  for which there  is only one spot each.  The blots were  then 
processed and hybridized  with the Bam H 1 V fragment of the EBV genome by standard 
techniques (see Materials and Methods). 56  EBV  AND  B  CELL  ACTIVATION 
TABLE  IV 
Effect of Metabolic Inhibitors on Expression of BLAST-2 (EBVCS) 
Inhibitor  BLAST-2  ÷ Cells  Inhibition 
Arabinoside C (1 #g/ml)  12.1  7 
Control*  13.0 
Actinomycin D (1 gg/ml)  1.1  93 
Control*  16.4 
Cycloheximide (5 #g/ml)  2.4  75 
Control*  9.7 
* These  represent  three  separate  experiments  performed  at  different 
times,  therefore, the control  value for each  is  included.  The control 
represents the same cells infected in the absence of inhibitor. 
Discussion 
In this  report,  we show that  the in  vitro infection of B cells by EBV may be 
used to delineate events occurring during B cell activation, and conversely, that 
surface markers of B cell differentiation may be used as probes for analyzing the 
early events in EBV infection.  In our previous studies (13) we have shown that 
the BLAST-2 (EBVCS) antigen appears before blastogenesis on B cells that have 
been activated by a  variety of agents.  However, it was not possible to conclude 
that these cells were destined to undergo blastogenesis.  Using the EBV system, 
we have now shown this to be true.  Furthermore,  we suggest that this is typical 
for activation  of B  cells  by any  other  agent.  We have  isolated  the  BLAST-2 
(EBVCS)  + population  early  in  infection,  and  demonstrated  that  it  consists  of 
small diploid B cells, clearly distinct from proliferating lymphoblasts. These cells 
contain high levels of RNA, multiple copies of the viral genome, and express the 
viral  genetic  information  (EBNA).  Furthermore,  they clone with a  frequency 
similar to that  of a  recently established EBV-infected cell line.  By comparison, 
the BLAST-2 (EBVCS)- population  did not immortalize  or contain detectable 
viral genomes, although a large fraction of the cells expressed EBNA and elevated 
levels  of RNA.  The  observation  that  a  substantial  number  of EBV-infected 
EBNA  + cells do not proliferate is in agreement with similar conclusions drawn 
by Robinson and Smith (18), based on kinetic studies. The presence of EBNA in 
some of the BLAST-2 (EBVCS)- cells implies the presence of viral genomes at a 
low copy number. This would have to be of the order of one genome per cell in 
order to remain  undetectable in our experiment.  This number is considerably 
lower than the average copy number in the BLAST-2 (EBVCS)  + population. We 
conclude, therefore, that BLAST-2 (EBVCS) is the earliest B cell-specific marker 
for  activated  cells,  and  defines a  stage  equivalent  to  entry  into  an  early  G~. 
Furthermore, it is a reliable indicator for immortalization by EBV. The blocking 
of antigen  expression  by inhibitors  of RNA and protein  synthesis implies that 
the antigen may be newly synthesized rather than cryptic. 
The  stage of activation  defined by BLAST-2 (EBVCS) has some features  in 
common  with  early  G1,  as  described  by  others  (1,  2).  These  authors  have 
described a stage that occurs soon after the activating signal, and is characterized 
by increased  RNA synthesis in  nondividing  cells.  However,  these authors  also 
describe these cells as having increased size, thus distinguishing  them from the 
still  small BLAST-2 (EBVCS)  ÷ cells. THORLEY-LAWSON  AND  MANN  57 
We have noted (l 3) that anti-BLAST-2 (EBVCS) gave an intense reaction in 
stains of histologic cross sections of lymph nodes. This stain was restricted to the 
germinal  centers,  as is  expected for  a  B  cell-specific antigen  that  appears  on 
lymphoblasts.  However, stain was also seen associated with an occasional cell in 
the  mantle  zone,  which  contains  small  B  cells.  We  were able  to  exclude  the 
possibilities that this reaction was due to the presence of a few B lymphoblasts or 
a  small  population  of BLAST-2  (EBVCS)  +  PBL-B  cells.  On  the  basis  of the 
present  study,  we  may  hypothesize  that  the  BLAST-2  (EBVCS)  ÷ cells in  the 
mantle zone may represent antigen-activated  B cells that have not yet migrated 
into the germinal center and undergone blastogenesis. 
Chronic lymphocyte leukemia (CLL) of B cell origin was thought to arise from 
a cell equivalent to the small circulating peripheral  B cell; nevertheless, we have 
shown  previously  (12,  13)  that  these  cells  express  the  BLAST  antigens.  We 
suggest, therefore, that the B CLL may be equivalent to the activated peripheral 
B cell that  has not yet undergone  blast transformation,  but would still express 
the BLAST-2 (EBVCS) antigen. 
The studies discussed above indicate that the EBV system can be used to study 
events in B cell activation, and that this information may then be used to interpret 
findings obtained with other more immunologically relevant systems. Conversely, 
we are currently using the BLAST antigens as probes for studying the virology 
of the early events in EBV infection. 
The conversion of normal cells into tumor cells has been shown in many cases 
to be due to the inappropriate  expression of cellular genes (oncogenes) or their 
viral  counterparts.  It  remains  to  be  seen  whether  the  inappropriate  level  of 
expression of the BLAST-1 and BLAST-2 (EBVCS) antigens during EBV infec- 
tion  plays  a  direct  role  in  the  immortalization  process,  in  addition  to  their 
presumed role in transformation/activation.  The alternative explanation  is that 
the appearance  of BLAST-1  and  BLAST-2  (EBVCS), being concomitant  with 
activation,  occurs automatically when  B  cells move from a  resting  state to the 
lymphoblastoid stage.  The  aberrant  levels of the antigens  in an autonomously 
replicating,  EBV-infected cell would then simply reflect loss of control of gene 
expression during the immortalization process. 
In  conclusion,  we  have  described  two  B  cell-specific  antigens  that  define 
different stages of activation of human B cells. In this paper, we have shown that 
BLAST-2 (EBVCS) appears on the resting cell soon after the activation signal. 
This cell then proceeds to undergo blast transformation  which, we have shown 
previously (12), is associated with the expression of the BLAST-1 antigen.  Both 
of the  antigens  are  expressed  at  aberrantly  high  levels only on  EBV-infected 
cells.  It  is  likely  that  these  two  molecules  play  important  roles  both  in  the 
mechanism of normal B cell activation, and of EBV-induced immortalization. 
Summary 
We have  used  Epstein-Barr  virus  (EBV)  infection  in  vitro  to  delineate  two 
distinct stages in B cell activation. Previous studies have shown that the BLAST- 
2 (EBVCS) (EBV cell surface) activation antigen is expressed on a small fraction 
of B cells within 24 h of stimulation with a variety of agents, including mitogens 
and  EBV.  In this study, we have been able to isolate the  BLAST-2 (EBVCS)  ÷ 
cells early after activation/infection with EBV. These cells are small B cells that 58  EBV  AND  B CELL ACTIVATION 
are actively synthesizing RNA but not DNA, and are, therefore, clearly distinct 
from large proliferating lymphoblasts.  In addition, they contain multiple copies 
of  the  EBV  genome,  express  the  viral  nuclear  antigen  (EBNA)  and,  most 
importantly, proceed to undergo  transformation when placed back in culture. 
By comparison, the BLAST-2 (EBVCS)- population does not undergo transfor- 
mation,  even though a  fraction of these cells are activated for RNA  synthesis 
and express  EBNA.  Thus,  using the  EBV  system,  we have been able to show 
directly that an activated B  cell first expresses the BLAST-2 (EBVCS) antigen 
concomitant with an increase in RNA synthesis, and then subsequently proceeds 
to differentiate into a proliferating lymphoblast. 
The authors would like to thank Yvonne Jones for typing this manuscript. 
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